¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Primarily systemic agent, unspecified"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • systemic lupus erythematosus
    Àü½ÅÈ«¹Ý·çǪ½º
  • systemic mastocytosis
    Àü½Åºñ¸¸¼¼Æ÷Áõ
  • systemic nodular panniculitis
    Àü½Å°áÀýÁö¹æÃþ¿°
  • systemic reaction
    Àü½Å¹ÝÀÀ
  • systemic scleroderma
    Àü½ÅÇǺΰæÈ­Áõ
  • systemic sclerosis
    Àü½Å°æÈ­Áõ
  • systemic therapy
    Àü½Å¿ä¹ý
  • systemic treatment
    Àü½ÅÄ¡·á
  • systemic vein
    Àü½ÅÁ¤¸Æ, üÁ¤¸Æ
  • anorectic agent
    ½Ä¿å¾ïÁ¦Á¦
  • antiallergic agent
    ¾Ë·¹¸£±â¾à
  • antiarrhythmic agent
    Ç׺ÎÁ¤¸ÆÁ¦
  • antiasthmatic agent
    Ç×õ½ÄÁ¦
  • antifoaming agent
    Ç×±âÆ÷Á¦, ±âÆ÷Á¦°ÅÁ¦
  • antifungal agent
    Ç×Áø±ÕÁ¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antifungal agent
    Ç×Áø±ÕÁ¦
  • antimetabolic agent
    Ç×´ë»ç¹°Áú
  • antitumor agent
    Ç×¾ÏÁ¦
  • blocking agent
    Â÷´ÜÁ¦
  • etiologic agent
    ¿øÀÎü, º´ÀÎü
  • hyperosmotic agent
    °í»ïÅõ¾ÐÁ¦
  • induction agent
    À¯µµ¹°Áú
  • infectious agent
    °¨¿°Ã¼, °¨¿°¿ø
  • oxidizing agent
    »êÈ­Á¦
  • pressor agent
    ½Â¾ÐÁ¦, Ç÷¾Ð»ó½ÂÁ¦
  • sclerosing agent
    °æÈ­Á¦
  • tocolytic agent
    ÀڱüöÃà¾ïÁ¦Á¦
  • toxic agent
    µ¶¹°, µ¶±Ø¹°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • systemic mastocytosis
    Àü½Åºñ¸¸¼¼Æ÷Áõ
  • progressive systemic sclerosis
    (¢¡systemic scleroderma) Àü½ÅÇǺΰæÈ­Áõ
  • systemic nodular panniculitis
    Àü½Å°áÀýÁö¹æÃþ¿°
  • systemic reaction
    Àü½Å¹ÝÀÀ
  • systemic scleroderma
    Àü½ÅÇǺΰæÈ­Áõ
  • systemic sclerosis
    (¢¡systemic scleroderma) Àü½ÅÇǺΰæÈ­Áõ
  • systemic therapy
    Àü½Å¿ä¹ý
  • systemic treatment
    Àü½ÅÄ¡·á
  • agent
    ¾à¹°, ¾àÁ¦, ¹°Áú, ÀÎÀÚ, ¹ß»ý¿ø
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦
  • alkylating agent
    ¾Ëųȭ¾à¹°, ¾ËųȭÁ¦
  • anesthetic agent
    ¸¶ÃëÁ¦
  • anorectic agent
    ½Ä¿å°¨ÅðÁ¦
  • anti-inflammatory agent
    Ç׿°ÁõÁ¦, ¼Ò¿°Á¦, ¿°Áõ¾à
  • antiallergic agent
    ¾Ë·¹¸£±â¾à
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å°æÈ­Áõ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å¼º °æÈ­Áõ(òäú¼àõ îñãóàõ Ìãûùñø)
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å¼º °æÈ­Áõ(òäú¼àõîñãóàõÌãûùñø).
  • reactive systemic amyloidosis
    ¹ÝÀÀ¼º Àü½Å À¯ÀüºÐÁõ
  • Eaton agent
    ÀÌÆ°º´¿øÃ¼.
  • Eatons agent
    ÀÌÆ°º´¿øÃ¼.
  • Eatons agent
    ÀÌÆ°º´¿øÃ¼.
  • Eatons agent
    ÀÌÆ° º´¿øÃ¼
  • Eatons agent pneumonia
    ÀÌÆ°º´¿øÃ¼Æó·Å.
  • Norwalk agent
    ³ë¿öÅ© º´¿øÃ¼
  • Norwalk-like agent
    ³ë¸£¿ÍÅ©¾ç ü
  • Parvovirus-like agent
    ÆÄº¸¹ÙÀÌ·¯½º¾ç º´¿øÃ¼
  • Pittsburgh pneumonia [agent]
    ÇÇÃ÷¹ö±×Æó·Å(¿øÀÎü), ·¹Áö¿À³Ú¶óÁõ(¿øÀÎü)
  • addition agent
    ÷°¡Á¦(ôÕÊ¥ð¥).
  • alpha-sympathomimetic agent
    ¾ËÆÄ±³°¨½Å°æÀ¯»çÀÛ¿ëÁ¦
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • non-organ specific or systemic
    Àå±â ºñƯÀ̼ºÀÇ, Àü½ÅÀûÀÇ
  • passive systemic anaphylaxis
    ¼öµ¿Àü½Å¾Æ³ªÇʶô½Ã½º
  • portal-systemic encephlopathy
    ¹®¸Æ-Àü½Å¼øÈ¯¼º ³úº´Áõ(Ú¦Øæ-îïãóâàü»àõ ÒàÜ»ñø)
  • porto-systemic shunt
    ¹®¸ÆÃ¼´Ü¶ô(Ó­Õ©)<--¼ÇÆ®>
  • primary systemic amyloidosis
    ¿ø¹ß¼º Àü½Å À¯ÀüºÐÁõ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å°æÈ­Áõ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å¼º °æÈ­Áõ(òäú¼àõ îñãóàõ Ìãûùñø)
  • progressive systemic sclerosis
    ÁøÇà(¼º) Àü½Å°æÈ­Áõ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å¼º °æÈ­Áõ(òäú¼àõîñãóàõÌãûùñø).
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å °æÈ­Áõ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å¼º °æÈ­Áõ(Ìãûùñø)
  • reactive systemic amyloidosis
    ¹ÝÀÀ¼º Àü½Å À¯ÀüºÐÁõ
  • sclerosing medial calcific,progressive systemic
    ÁøÇ༺ Àü½Å¼º(òäú¼àõ îïãóàõ)
  • secondary systemic amyloidosis
    ¼Ó¹ß¼º Àü½Å¼º(áÙÛ¡àõîïãóàõ) ¾Æ¹Ð·ÎÀ̵åÁõ.
  • secondary systemic amyloidosis
    ¼Ó¹ß¼º Àü½Å¼º(áÙÛ¡àõîïãóàõ) ¾Æ¹Ð·ÎÀ̵åÁõ(¡­ñø)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • emulsifying agent
    ¿¡¸ÖÁ¯È­Á¦(ûùð¥)
  • F agent
    F Á¦(ð¥)
  • fusogenic agent
    À¶ÇÕ »ý¼ºÁ¦(ë×ùêßæà÷ð¥)
  • germicidal agent
    »ì±ÕÁ¦(߯жð¥)
  • immunosuppressive agent
    ¸é¿ª¾ï¾ÐÁ¦(Øóæ¹åääâð¥)
  • lipotropic agent
    ÁöÁúµ¿¿øÁ¦(ò·òõÔÑê¬ð¥)
  • lympholytic agent
    ¸²ÇÁ±¸¿ëÇØÁ¦(éÁú°ð­)
  • lysosomotropic agent
    ¶óÀ̼ÒÁ»ÀÚ±ØÁ¦(í©Ð»ð¥)
  • methylating agent
    ¸ÞƿȭÁ¦(ð¥)
  • mutagenic agent
    º¯ÀÌ¿øÁ¦(ܨì¶ê«ð¥)
  • oxidizing agent
    »êÈ­Á¦(ß«ûùð¥)
  • precipitating agent
    ħ°­Á¦(öØË½ð¥)
  • pressor agent
    Ç÷¾Ð»ó½ÂÁ¦(úìäâß¾ã°ð¥)
  • reducing agent
    ȯ¿ø ½Ã¾à(ü½êªãËå·)
  • sequestering agent
    °ÝÀýÇü¼ºÁ¦(̰ï¾û¡à÷ð¥)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • etiologic agent
    º´ÀÎü
  • gadolinium based contrast agent
    °¡µ¹¸®´½Á¶¿µÁ¦
  • immunosuppressive agent
    ¸é¿ª¾ïÁ¦¾à, ¸é¿ª¾ïÁ¦ÀÎÀÚ
  • paramagnetic agent
    »óÀÚ¼ºÁ¦Àç
  • protective agent
    º¸È£¾à, ÇÇÆ÷¾à
  • radioopaque agent
    ¹æ»ç¼±ºñÅõ°ú¼ºÁ¦Àç
  • radioprotective agent
    ¹æ»ç¼±¹æÈ£Á¦
  • sclerosing agent
    °æÈ­¾à
  • therapeutic agent
    Ä¡·á¾à
  • thrombolytic agent
    Ç÷Àü¿ëÇØ¾à
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SSc systemic scleroderma; systemic sclerosis
DTIC Dimethyl Triazeno Imidazole Carboxamide
  ; Alkylating Agent
HDV Hepatitis D(elta) Virus
  = HBV associated Delta Agent
AAA abdominal aortic aneurysm/aneurysmectomy; acne-associated arthritis; acquired aplastic anemia; acute...
AAC antibiotic-associated [pseudomembranous] colitis; antimicrobial agent-induced colitis; augmentative ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
UCA ultrasound contrast agent
AA alkylating agent
BCA bifunctional chelating agent
CA contrast agent
CPA cryoprotective agent
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • systemic name
    Á¶Á÷¸í, °èÅë¸í
    È­ÇÐ ¹°Áú¸íÀ¸·Î¼­ Àû¿ëµÇ´Â °èÅë¸íÀº Ưº°È÷ ¸¸µé¾îÁø ¶Ç´Â ¼±Á¤µÈ ¸» ¶Ç´Â ¿ë¾î·Î ±¸¼ºµÇ¾î, ±× °¢°¢ÀÌ Á¤ÀÇµÈ È­ÇÐ ±¸Á¶ÀÇ Àǹ̸¦ °¡Áö°í Àֱ⠶§¹®¿¡, ±× ¸íĪÀ¸·ÎºÎÅÍ ±¸Á¶¸¦ ¾Ë ¼ö ÀÖ´Ù.
  • systemic related problem
    Àü½ÅÀû ¹®Á¦
  • systemic sclerosis
    Àü½Å¼º °æÈ­Áõ, °øÇÇÁõ. °æÇÇÁõ
    ÇǺÎ, ½ÉÀå, ½Äµµ, ½ÅÀå ¹× Æó¸¦ Æ÷ÇÔÇÑ ½Åü ¸ðµç ºÎÀ§ °áÇÕ Á¶Á÷ÀÇ ¸¸¼ºÀûÀÎ °æÈ­ ¹× À§Ãà. ÇǺδ ºñÈÄ, °æÈ­, °­Á÷µÇ°í Âø»öµÈ ¹ÝÀÌ »ý±ä´Ù. À̰ÍÀº Àü½Å¼ºÀÎ °æ¿ì »çÁöÀÇ ¸»´ÜºÎ³ª ¾ó±¼ ¶Ç´Â ¼Õ°¡¶ô¿¡ ±¹ÇÑµÈ °æ¿ì, EH´Â Á÷°æ ¼ö cmÀÇ l ³­Çü ¶Ç´Â ¼±»ó ¿µ¿ª¿¡ ±¹ÇÑ µÈ °æ¿ì°¡ ÀÖ´Ù.
  • systemic stage
    Àü½ÅÀûÀÎ »óÅÂ
  • systemic vasculitis
    Àü½Å¼º ¸Æ°ü¿°
  • systemic zoster
    Àü½Å¼º ´ë»ó Æ÷Áø
  • ulceration in systemic disease
    Àü½Å ÁúȯÀÇ ±Ë¾çÈ­
  • abetting agent
    Á¶Àå¹°
    ÁÖ ¾à¹°ÀÇ ¾àÈ¿¸¦ º¸Á¶Çϰí, ÁÖ ¾à¹°ÀÇ À¯ÇØÇÑ ÀÛ¿ëÀ» ¸·°Å³ª ¿ÏÈ­ÇÏ´Â ¸ñÀûÀ¸·Î »ç¿ëÇÏ´Â ¾à¹°.
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸° Â÷´ÜÁ¦
    ¾Æµå·¹³¯¸°¼º ¼ö¿ëü¿¡ ÀÛ¿ëÇÏ¿© ½Å°æ Àü´Þü¿Í ¼ö¿ëü°¡ °áÇÕÇÏÁö ¸øÇÏ°Ô ÇÔÀ¸·Î½á ±³°¨½Å°æ ÈïºÐ È¿°ú¸¦ ºÀ¼âÇÏ´Â ¾à¹°.
  • agent
    ¾à¹°, ¾à¹°Á¦, ÀÛ¿ë¹°Áú, º´ÀÎ
    ¹°¸®Àû, È­ÇÐÀû ¶Ç´Â »ý¹°ÇÐÀûÀÎ È¿°ú¸¦ ÀÏÀ¸Å°´Â Èû, ¼ººÐ ¶Ç´Â ¹°Áú.
  • anabolic agent
    µ¿È­ ¾à¹°
  • analgesic agent
    ÁøÅëÁ¦
    ½Å°æÀ» ¸¶ºñ½ÃÄÑ ¾ÆÇÄÀ» ÁøÁ¤½ÃŰ´Â ¾àÁ¦. ¸ôÇÉ, ¾ÈƼÇǸ° µîÀÌ ÀÖ´Ù.
  • anesthetic agent
    ¸¶Ãë¾à, ¸¶Ãë, ¸¶ÃëÁ¦
    µ¿ÀǾî=anesthetic drug.
  • anorexigenic agent
    ½Ä¿å ¾ïÁ¦Á¦
  • anti-inflammatory agent
    Ç׿°Áõ ¾à, ¼Ò¿°Á¦, Ç׿°ÁõÁ¦
    ¿°Áõ¿¡ ¹Ý´ë·Î ÀÛ¿ëÇϰųª ¿°ÁõÀ» ¾ïÁ¦ÇÏ´Â ¾àÁ¦.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
systemic mastocytosis Infiltration of many organ systems by mast cells with varied clinical manifestations that can include fever, weight loss, flushing, bronchospasm, rhinorrhoea, palpitations, dyspnea, diarrhoea, gastrointestinal bleeding, and hypotension.
Synonym: systemic mastocytosis.
(05 Mar 2000)
systemic myelitis Inflammation confined to special tracts of the spinal cord.
(05 Mar 2000)
systemic-onset juvenile chronic arthritis See: Systemic-onset juvenile rheumatoid arthritis (still's disease).
(12 Dec 1998)
systemic-onset juvenile rheumatoid arthritis <rheumatology> A form of joint disease, arthritis, that presents with systemic upset.
Clinical signs: high intermittent fever, a salmon-coloured skin rash, swollen lymph glands, enlargement of the liver and spleen, and inflammation of the lungs (pleuritis) and around the heart (pericarditis).
The arthritis itself may not be immediately apparent but once apparent, it may persist after the systemic symptoms have resolved.
Synonym: Still's disease.
(03 Jul 1999)
systemic poisoning Any disease of toxic origin.
Synonym: systemic poisoning.
Origin: toxico-+ G. -osis, condition
(05 Mar 2000)
systemic sclerosis <rheumatology> A multisystem disorder of unknown aetiology. It is characterised by fibrosis (scarring) of the skin, blood vessels and internal organs. Involvement of the gastrointestinal tract, heart, kidneys and lungs is common.
(09 Jan 1998)
systemic therapy <pharmacology> Treatment that reaches and affects cells all over the body.
(16 Dec 1997)
systemic vascular resistance An index of arteriolar compliance or constriction throughout the body; equal to the blood pressure divided by the cardiac output.
(05 Mar 2000)
systemic venous hypertension Increased pressure in the veins ultimately leading to the right atrium nearly always due to disease of the right heart but occasionally due to blockade of one or both venae cavae.
(05 Mar 2000)
juvenile chronic arthritis, systemic-onset See: Juvenile rheumatoid arthritis, systemic-onset (still's disease).
(12 Dec 1998)
juvenile rheumatoid arthritis, systemic-onset Also known as systemic-onset juvenile chronic arthritis. Still's disease presents with systemic (bodywide) illness including high intermittent fever, a salmon-coloured skin rash, swollen lymph glands, enlargement of the liver and spleen, and inflammation of the lungs (pleuritis) and around the heart (pericarditis). The arthritis may not be immediately apparent but it does always surface and it may persists long after the systemic symptoms are gone.
(12 Dec 1998)
lupus erythematosus, systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterised principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown aetiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of le cells in the blood or bone marrow.
(12 Dec 1998)
adrenergic blocking agent A compound that selectively blocks or inhibits responses to sympathetic adrenergic nerve activity (sympatholytic agent) and to epinephrine, norepinephrine, and other adrenergic amines (adrenolytic agent); two distinct classes exist, alpha-and beta-adrenergic receptor blocking agent's.
(05 Mar 2000)
adrenergic neuronal blocking agent A drug that prevents the release of norepinephrine from sympathetic nerve terminals; it does not inhibit the responses of the adrenergic receptors to circulating epinephrine, norepinephrine, and other adrenergic amines.
(05 Mar 2000)
agent <pharmacology> Any power, principle or substance capable of producing an effect, whether physical, chemical or biological.
Origin: L. Agens = acting
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • conversion agent
    Àüȯ ´ë¸® ±â°ü
  • county agent
    (¿¬¹æ.ÁÖÁ¤ºÎ°¡ ÆÄ°ßÇÑ)³ó»ç °í¹®
  • double agent
    ÀÌÁß °£Ã¸
  • estate agent
    ºÎµ¿»ê°ü¸®ÀÎ;Áß°³¾÷ÀÚ
  • fiscal agent
    À繫 ´ë¸® ±â°ü;À繫 ´ë¸®ÀÎ
  • forwarding agent
    ¿î¼Û¾÷ÀÚ
  • free agent
    ÀÚÁÖÀûÀÎ ÇàÀ§ÀÚ;ÀÚÀ¯°è¾à ¼±¼ö )
  • general agent
    ÃѴ븮ÀÎ
  • house agent
    º¹´ö¹æ;°¡¿Á ¸Å¸Å ¼Ò°³¾÷ÀÚ
  • inquiry agent
    (¿µ)»ç½Ç ŽÁ¤
  • insurance agent
    º¸Çè´ë¸®Á¡
  • land agent
    ÅäÁö ¸Å¸Å Áß°³¾÷ÀÚ;ÅäÁö °ü¸®ÀÎ
  • nerve agent
    (±º¿ëÀÇ)½Å°æ°è¿¡ ÀÛ¿ëÇÏ´Â ¹°Áú;½Å°æ°¡½º(µî)
  • parliamentary agent
    Á¤´çÀÇ ÀÇȸ ´ëº¯ÀÎ
  • press agent
    º¸µµ¿ø;¼±Àü¿ø
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á